142 related articles for article (PubMed ID: 38082337)
21. Active surveillance for the management of prostate cancer in a contemporary cohort.
Dall'Era MA; Konety BR; Cowan JE; Shinohara K; Stauf F; Cooperberg MR; Meng MV; Kane CJ; Perez N; Master VA; Carroll PR
Cancer; 2008 Jun; 112(12):2664-70. PubMed ID: 18433013
[TBL] [Abstract][Full Text] [Related]
22. Association of Prostate-Specific Antigen Velocity With Clinical Progression Among African American and Non-Hispanic White Men Treated for Low-Risk Prostate Cancer With Active Surveillance.
Nelson TJ; Javier-DesLoges J; Deka R; Courtney PT; Nalawade V; Mell L; Murphy J; Parsons JK; Rose BS
JAMA Netw Open; 2021 May; 4(5):e219452. PubMed ID: 33999164
[TBL] [Abstract][Full Text] [Related]
23. The Clinical Significance of Multiple Negative Surveillance Prostate Biopsies for Men on Active Surveillance-Does Cancer Vanish or Simply Hide?
Chu CE; Cowan JE; Fasulo V; Washington SL; de la Calle C; Shoemaker J; Carroll PR
J Urol; 2021 Jan; 205(1):109-114. PubMed ID: 33198555
[TBL] [Abstract][Full Text] [Related]
24. Active surveillance in men with localized prostate cancer: a systematic review.
Dahabreh IJ; Chung M; Balk EM; Yu WW; Mathew P; Lau J; Ip S
Ann Intern Med; 2012 Apr; 156(8):582-90. PubMed ID: 22351515
[TBL] [Abstract][Full Text] [Related]
25. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression.
Choo R; Klotz L; Danjoux C; Morton GC; DeBoer G; Szumacher E; Fleshner N; Bunting P; Hruby G
J Urol; 2002 Apr; 167(4):1664-9. PubMed ID: 11912384
[TBL] [Abstract][Full Text] [Related]
26. [Active surveillance in prostate cancer: Assessment of MRI in the selection and follow-up of patients].
Raichi A; Marcq G; Fantoni JC; Puech P; Villers A; Ouzzane A
Prog Urol; 2018 Jun; 28(8-9):416-424. PubMed ID: 29861328
[TBL] [Abstract][Full Text] [Related]
27. Medium-term outcomes of active surveillance for localised prostate cancer.
Selvadurai ED; Singhera M; Thomas K; Mohammed K; Woode-Amissah R; Horwich A; Huddart RA; Dearnaley DP; Parker CC
Eur Urol; 2013 Dec; 64(6):981-7. PubMed ID: 23473579
[TBL] [Abstract][Full Text] [Related]
28. Magnetic Resonance Imaging-Guided Confirmatory Biopsy for Initiating Active Surveillance of Prostate Cancer.
Jayadevan R; Felker ER; Kwan L; Barsa DE; Zhang H; Sisk AE; Delfin M; Marks LS
JAMA Netw Open; 2019 Sep; 2(9):e1911019. PubMed ID: 31509206
[TBL] [Abstract][Full Text] [Related]
29. Value of Serial Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging-guided Biopsies in Men with Low-risk Prostate Cancer on Active Surveillance After 1 Yr Follow-up.
Hamoen EHJ; Hoeks CMA; Somford DM; van Oort IM; Vergunst H; Oddens JR; Smits GA; Bokhorst LP; Witjes JA; Rovers MM; Hulsbergen-van de Kaa CA; Barentsz JO
Eur Urol Focus; 2019 May; 5(3):407-415. PubMed ID: 29331622
[TBL] [Abstract][Full Text] [Related]
30. Updated clinical results of active surveillance of very-low-risk prostate cancer in Korean men: 8 years of follow-up.
Ha JY; Shin TJ; Jung W; Kim BH; Park CH; Kim CI
Investig Clin Urol; 2017 May; 58(3):164-170. PubMed ID: 28480341
[TBL] [Abstract][Full Text] [Related]
31. Active Surveillance for Prostate Cancer: How to Do It Right.
Garisto JD; Klotz L
Oncology (Williston Park); 2017 May; 31(5):333-40, 345. PubMed ID: 28512731
[TBL] [Abstract][Full Text] [Related]
32. Best Current Practice and Research Priorities in Active Surveillance for Prostate Cancer-A Report of a Movember International Consensus Meeting.
Moore CM; King LE; Withington J; Amin MB; Andrews M; Briers E; Chen RC; Chinegwundoh FI; Cooperberg MR; Crowe J; Finelli A; Fitch MI; Frydenberg M; Giganti F; Haider MA; Freeman J; Gallo J; Gibbs S; Henry A; James N; Kinsella N; Lam TBL; Lichty M; Loeb S; Mahal BA; Mastris K; Mitra AV; Merriel SWD; van der Kwast T; Van Hemelrijck M; Palmer NR; Paterson CC; Roobol MJ; Segal P; Schraidt JA; Short CE; Siddiqui MM; Tempany CMC; Villers A; Wolinsky H; MacLennan S
Eur Urol Oncol; 2023 Apr; 6(2):160-182. PubMed ID: 36710133
[TBL] [Abstract][Full Text] [Related]
33. Guy's and St Thomas NHS Foundation active surveillance prostate cancer cohort: a characterisation of a prostate cancer active surveillance database.
Shah S; Beckmann K; Van Hemelrijck M; Challacombe B; Popert R; Dasgupta P; Rusere J; Zisengwe G; Elhage O; Santaolalla A
BMC Cancer; 2021 May; 21(1):573. PubMed ID: 34011308
[TBL] [Abstract][Full Text] [Related]
34. Early diagnosis of prostate cancer in the Western Cape.
Heyns CF; Naudé AM; Visser AJ; Marais DC; Stopforth HB; Nyarko JK; Stellmacher GA
S Afr Med J; 2001 Aug; 91(8):679-84. PubMed ID: 11584784
[TBL] [Abstract][Full Text] [Related]
35. Active surveillance should be considered for select men with Grade Group 2 prostate cancer.
Pekala KR; Bergengren O; Eastham JA; Carlsson SV
BMC Urol; 2023 Sep; 23(1):152. PubMed ID: 37777716
[TBL] [Abstract][Full Text] [Related]
36. A Multivariable Approach Using Magnetic Resonance Imaging to Avoid a Protocol-based Prostate Biopsy in Men on Active Surveillance for Prostate Cancer-Data from the International Multicenter Prospective PRIAS Study.
Luiting HB; Remmers S; Boevé ER; Valdagni R; Chiu PK; Semjonow A; Berge V; Tully KH; Rannikko AS; Staerman F; Roobol MJ
Eur Urol Oncol; 2022 Dec; 5(6):651-658. PubMed ID: 35437217
[TBL] [Abstract][Full Text] [Related]
37. Follow-up in Active Surveillance for Prostate Cancer: Strict Protocol Adherence Remains Important for PRIAS-ineligible Patients.
Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
Eur Urol Oncol; 2019 Sep; 2(5):483-489. PubMed ID: 31411970
[TBL] [Abstract][Full Text] [Related]
38. [Active surveillance for low-risk prostate cancer].
Herlemann A; Stief CG
Urologe A; 2016 Feb; 55(2):269-81. PubMed ID: 26831055
[TBL] [Abstract][Full Text] [Related]
39. The Use of Multiparametric Magnetic Resonance Imaging for Follow-up of Patients Included in Active Surveillance Protocol. Can PSA Density Discriminate Patients at Different Risk of Reclassification?
Roscigno M; Stabile A; Lughezzani G; Pepe P; Galosi AB; Naselli A; Naspro R; Nicolai M; La Croce G; Aljoulani M; Perugini G; Guazzoni G; Montorsi F; Balzarini L; Sironi S; Da Pozzo LF
Clin Genitourin Cancer; 2020 Dec; 18(6):e698-e704. PubMed ID: 32493676
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]